Downregulation of miR-145 contributes to lung adenocarcinoma cell growth to form brain metastases

Oncology Reports

Volumn 30, Issue 5, 2013, Pages 2027-2034

  Zhao, Chunyang ^a   Xu, Yan ^a,b   Zhang, Yongqiang ^a   Tan, Weiwei ^a,b   Xue, Jianxin ^b   Yang, Zongze ^a,b   Zhang, You ^a,b   Lu, You ^b   Hu, Xun ^a,b  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

Author keywords

Brain metastasis; Cell proliferation; MicroRNA; MiR 145; Primary lung adenocarcinoma

Indexed keywords

MICRORNA; MICRORNA 145; MICRORNA 1471; MICRORNA 214; MICRORNA 23A; MICRORNA 3656; MICRORNA 718; MICRORNA 720; MICRORNA 9; UNCLASSIFIED DRUG;

ADULT; ANALYTICAL EQUIPMENT; ARTICLE; BRAIN METASTASIS; CANCER CELL CULTURE; CARCINOGENESIS; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL SPECIFICITY; CELL STRAIN A549; CELL STRAIN SPC A1; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LUNG ADENOCARCINOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; MOLECULAR PATHOLOGY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; UPREGULATION;

ADENOCARCINOMA; ADULT; BRAIN NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; CELL PROLIFERATION; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MICRORNAS; MIDDLE AGED; UP-REGULATION;

EID: 84885031699     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2728     Document Type: Article

References (47)

1. Bartel DP: MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116: 281-297, 2004.
2. Lai EC: MicroRNAs are complementary to 3' UTR sequence motifs that mediate negative post-transcriptional regulation. Nat Genet 30: 363-364, 2002.
3. Berezikov E, Guryev V, van de Belt J, Wienholds E, Plasterk RH and Cuppen E: Phylogenetic shadowing and computational identification of human microRNA genes. Cell 120: 21-24, 2005.
4. Xie X, Lu J, Kulbokas EJ, Golub TR, Mootha V, Lindblad-Toh K, Lander ES and Kellis M: Systematic discovery of regulatory motifs in human promoters and 3' UTRs by comparison of several mammals. Nature 434: 338-345, 2005.
5. Shi XB, Tepper CG and deVere White RW: Cancerous miRNAs and their regulation. Cell Cycle 7: 1529-1538, 2008.
6. Hwang HW and Mendell JT: MicroRNAs in cell proliferation, cell death, and tumorigenesis. Br J Cancer 94: 776-780, 2006.
7. Mezzanzanica D, Bagnoli M, De Cecco L, Valeri B and Canevari S: Role of microRNAs in ovarian cancer pathogenesis and potential clinical implications. Int J Biochem Cell Biol 42: 1262-1272, 2010.
8. Chen X, Gong J, Zeng H, et al: MicroRNA145 targets BNIP3 and suppresses prostate cancer progression. Cancer Res 70: 2728-2738, 2010.
9. Dong Q, Meng P, Wang T, et al: MicroRNA let-7a inhibits proliferation of human prostate cancer cells in vitro and in vivo by targeting E2F2 and CCND2. PLoS One 5: e10147, 2010.
10. Nicoloso MS, Spizzo R, Shimizu M, Rossi S and Calin GA: MicroRNAs - the micro steering wheel of tumour metastases. Nat Rev Cancer 9: 293-302, 2009.
11. Patchell RA: The management of brain metastases. Cancer Treat Rev 29: 533-540, 2003.
12. Nathoo N, Chahlavi A, Barnett GH and Toms SA: Pathobiology of brain metastases. J Clin Pathol 58: 237-242, 2005.
13. Schouten LJ, Rutten J, Huveneers HA and Twijnstra A: Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma. Cancer 94: 2698-2705, 2002.
14. Smedby KE, Brandt L, Bäcklund ML and Blomqvist P: Brain metastases admissions in Sweden between 1987 and 2006. Br J Cancer 101: 1919-1924, 2009.
15. Penel N, Brichet A, Prevost B, Duhamel A, Assaker R, Dubois F and Lafitte JJ: Pronostic factors of synchronous brain metastases from lung cancer. Lung Cancer 33: 143-154, 2001.
16. Steeg PS: Tumor metastasis: mechanistic insights and clinical challenges. Nat Med 12: 895-904, 2006.
17. Chambers AF, Groom AC and MacDonald IC: Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2: 563-572, 2002.
18. Braun S, Vogl FD, Naume B, et al: A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med 353: 793-802, 2005.
19. Roodman GD: Mechanisms of bone metastasis. Discov Med 4: 144-148, 2004.
20. Fidler IJ: Modulation of the organ microenvironment for treatment of cancer metastasis. J Natl Cancer Inst 87: 1588-1592, 1995.
21. Radinsky R: Molecular mechanisms for organ-specific colon carcinoma metastasis. Eur J Cancer 31: 1091-1095, 1995.
22. Radinsky R and Ellis LM: Molecular determinants in the biology of liver metastasis. Surg Oncol Clin N Am 5: 215-229, 1996.
23. Fitzgerald DP, Palmieri D, Hua E, Hargrave E, Herring JM, Qian Y, Vega-Valle E, Weil RJ, Stark AM, Vortmeyer AO and Steeg PS: Reactive glia are recruited by highly proliferative brain metastases of breast cancer and promote tumor cell colonization. Clin Exp Metastasis 25: 799-810, 2008.
24. Dykxhoorn DM, Wu Y, Xie H, et al: miR-200 enhances mouse breast cancer cell colonization to form distant metastases. PLoS One 4: e7181, 2009.
25. Wang H, Ach RA and Curry B: Direct and sensitive miRNA profiling from low-input total RNA. RNA 13: 151-159, 2007.
26. He TC, Zhou S, da Costa LT, et al: A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci USA 95: 2509-2514, 1998.
27. Lima RT, Busacca S, Almeida GM, Gaudino G, Fennell DA and Vasconcelos MH: MicroRNA regulation of core apoptosis pathways in cancer. Eur J Cancer 47: 163-174, 2011.
28. Varnholt H, Drebber U, Schulze F, Wedemeyer I, Schirmacher P, Dienes HP and Odenthal M: MicroRNA gene expression profile of hepatitis C virus-associated hepatocellular carcinoma. Hepatology 47: 1223-1232, 2008.
29. Liu X, Sempere LF, Galimberti F, et al: Uncovering growth-suppressive MicroRNAs in lung cancer. Clin Cancer Res 15: 1177-1183, 2009.
30. Dyrskjøt L, Ostenfeld MS, Bramsen JB, et al: Genomic profiling of microRNAs in bladder cancer: miR-129 is associated with poor outcome and promotes cell death in vitro. Cancer Res 69: 4851-4860, 2009.
31. Nam EJ, Yoon H, Kim SW, Kim H, Kim YT, Kim JH, Kim JW and Kim S: MicroRNA expression profiles in serous ovarian carcinoma. Clin Cancer Res 14: 2690-2695, 2008.
32. Arndt GM, Dossey L, Cullen LM, et al: Characterization of global microRNA expression reveals oncogenic potential of miR-145 in metastatic colorectal cancer. BMC Cancer 9: 374, 2009.
33. Götte M, Mohr C, Koo CY, et al: miR-145-dependent targeting of junctional adhesion molecule A and modulation of fascin expression are associated with reduced breast cancer cell motility and invasiveness. Oncogene 29: 6569-6580, 2010.
34. Wu BL, Xu LY, Du ZP, et al: MiRNA profile in esophageal squamous cell carcinoma: downregulation of miR-143 and miR-145. World J Gastroenterol 17: 79-88, 2011.
35. Sachdeva M and Mo YY: MicroRNA-145 suppresses cell invasion and metastasis by directly targeting mucin 1. Cancer Res 70: 378-387, 2010.
36. Fuse M, Nohata N, Kojima S, et al: Restoration of miR-145 expression suppresses cell proliferation, migration and invasion in prostate cancer by targeting FSCN1. Int J Oncol 38: 1093-1101, 2011.
37. Peng X, Guo W, Liu T, et al: Identification of miRs-143 and -145 that is associated with bone metastasis of prostate cancer and involved in the regulation of EMT. PLoS One 6: e20341, 2011.
38. Kano M, Seki N, Kikkawa N, et al: miR-145, miR-133a and miR-133b: Tumor-suppressive miRNAs target FSCN1 in esophageal squamous cell carcinoma. Int J Cancer 127: 2804-2814, 2010.
39. Akagi I, Miyashita M, Ishibashi O, et al: Relationship between altered expression levels of MIR21, MIR143, MIR145, and MIR205 and clinicopathologic features of esophageal squamous cell carcinoma. Dis Esophagus 24: 523-530, 2011.
40. Chiyomaru T, Enokida H, Tatarano S, et al: miR-145 and miR-133a function as tumour suppressors and directly regulate FSCN1 expression in bladder cancer. Br J Cancer 102: 883-891, 2010.
41. Cho WC, Chow AS and Au JS: Restoration of tumour suppressor hsa-miR-145 inhibits cancer cell growth in lung adenocarcinoma patients with epidermal growth factor receptor mutation. Eur J Cancer 45: 2197-2206, 2009.
42. Cho WC, Chow AS and Au JS: MiR-145 inhibits cell proliferation of human lung adenocarcinoma by targeting EGFR and NUDT1. RNA Biol 8: 125-131, 2011.
43. Fidler IJ: Seed and soil revisited: contribution of the organ microenvironment to cancer metastasis. Surg Oncol Clin N Am 10: 257-269, 2001.
44. Radinsky R: Modulation of tumor cell gene expression and phenotype by the organ-specific metastatic environment. Cancer Metastasis Rev 14: 323-338, 1995.
45. Gupta GP and Massagué J: Cancer metastasis: building a framework. Cell 127: 679-695, 2006.
46. Poste G and Fidler IJ: The pathogenesis of cancer metastasis. Nature 283: 139-146, 1980.
47. Fidler IJ: The organ microenvironment and cancer metastasis. Differentiation 70: 498-505, 2002.